Articles related to Endocrinology, Diabetes, Metabolism

In comparison to 72% of patients who received placebo, 45% of those who received teplizumab-mzwv (Tzield, Provention Bio) over the course of a median follow-up of 51 months were found to have stage 3 type 1 diabetes. Teplizumab-mzwv appeared to delay the onset of type 1 diabetes by about two years, as the median time from randomization to diagnosis of stage 3 diabetes was 50 months in the teplizumab-mzwv group and 25 months in the placebo group.

MDLinx compiled a reading list of captivating books that have nothing to do with medicine—but might just help physicians realize some things about their work — and life.

Looking at 2,500 case patients mapped to more than 45,000 controls, the hazard ratio for all thyroid cancers in GLP-1 users was 1.46. The hazard ratio for developing thyroid cancer with DPP-4 inhibitors was 1.1. GLP-1 receptors are present in normal and cancerous thyroid cells.

This case review highlights the differential diagnosis with lesions of this kind, together with management and clinical pearls.

The statin group experienced an average LDL-C reduction of 37.9%, according to the results of the single-center, prospective, randomized, single-blind SPORT study (Supplements, Placebo, or Rosuvastatin), while those who took dietary supplements experienced LDL-C changes similar to those in the placebo group. Additionally, rosuvastatin-treated patients experienced average decreases in triglycerides of 19% and total cholesterol of 24%. For any of the supplements, there were no differences in either total cholesterol or triglycerides when compared to placebo.

The extra calories and lower physical activity of modern culture are yielding higher rates of obesity, type 2 diabetes, heart disease, and other illnesses. Evidence is mounting that intermittent fasting may help reverse these trends. This neuroscientist brings 25 of studying intermittent fasting to explain why and how it works, and what your patients’ options are.